Favorable outcome in PLA2R positive HBV-associated membranous nephropathy

BMC Nephrology

Table 1 Clinical characteristics of the 7 patients with PLA2R positive HBV-MN

Patient				At the time of renal biopsy								Treatment	Follow-up
Patient	Sex	age	UP (g/24)	Urine RBC (μL ^-1)	ALB (g/L)	SCr (μmol/L)	C3 (g/L)	C4 (g/L)	HBV-DNA (IU/mL)	HBsAg /HBeAg	PLA2R-Ab titer		Time (month)	PR (month)	CR (month)	Renal insufficiency
1	F	30	4.97	1-2/HP	24	44	ND	ND	1.01×10⁸	+/+	1:100	ETV+ARB	61	9	23	N
2	F	31	7.78	351.5	20	48	0.82	0.18	7.9×10⁷	+/+	1:1000	ETV+ARB	46	14	28	N
3	M	33	9.48	90.8	17	82	0.55	0.13	6.45×10³	+/-	1:1000	ETV+ARB	45	33		N
4	F	45	8.09	84.8	27	47	1.53	0.35	2.8×10³	+/-	1:1000	ETV+ARB	97	25	52	N
5	F	54	3.9	155.9	26	53	1.08	0.28	UD	+/-	1:1000	ETV+ARB	24	24		N
6	F	59	4.00	32.3	22	50	1.15	0.30	UD	+/-	ND	LdT→ETV+ARB	58	24		N
7	M	69	19.65	98.2	16	121	0.69	0.31	UD	+/-	1:1000	ETV+ARB+ (FK506 + P→ CTX + P)	97	17	33	N

F Female, M Male, UP Urine protein, RBC Red blood cell, ALB Serum Albumin, SCr Serum creatinine, HBV Hepatitis B virus, HBsAg Hepatitis B virus surface antigen, HBeAg Hepatitis B virus e antigen, PLA2R-Ab Phospholipase A2 receptor antibody, HP High power, UD Undetectable, ND No data, ETV Entecavir, LdT Telbivudine, P Prednisone, CTX Cyclophosphamide, PR Partial remission, CR Complete remission, ARB Angiotensin receptor blocker, N No

ISSN: 1471-2369